Premium
Ticagrelor monotherapy in patients undergoing percutaneous coronary intervention for bifurcation lesions
Author(s) -
Piccolo Raffaele,
Esposito Giovanni
Publication year - 2020
Publication title -
catheterization and cardiovascular interventions
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.988
H-Index - 116
eISSN - 1522-726X
pISSN - 1522-1946
DOI - 10.1002/ccd.29082
Subject(s) - ticagrelor , medicine , aspirin , percutaneous coronary intervention , cardiology , clopidogrel , myocardial infarction
Key Points Ticagrelor monotherapy after a short course of aspirin is emerging as the predominant aspirin‐free strategy among patients undergoing percutaneous coronary intervention. In patients included in the GLOBAL‐LEADERS trial, the treatment effect of the experimental (dual antiplatelet therapy with aspirin and ticagrelor for 1 month followed by ticagrelor monotherapy) versus control strategy remained consistent irrespective of the presence or absence of coronary bifurcation. Ticagrelor monotherapy represents a safe and effective antiplatelet strategy for the treatment of patients who undergo percutaneous coronary intervention of bifurcation lesions.